ZIM Laboratories has planned strategic investments in Australia and the Middle East/North Africa (MENA) region to expand its presence in Developed and Pharmerging markets. For Australia and New Zealand markets, ZIM’s Board has approved an investment in a local startup company to enhance its registration, marketing, distribution, and sales capabilities for New Innovative Products (NIP) and Oral Thin Films (OTF). The investment grants ZIM 99% ownership of the company.
In the MENA region, ZIM's subsidiary, ZIM Laboratories FZE, Sharjah, will invest and partner with a local experienced business entrepreneur, through a step-down majority owned subsidiary, to obtain regulatory approvals and facilitate marketing, distribution, and sales of its various products in specific regional markets. These initiatives signify the company's growth plans and its aim to introduce innovative products for expansion across new markets.
ZIM Laboratories manufactures, formulates, and distributes drug delivery systems to develops generic pharmaceutical products.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |